Status:

RECRUITING

Antidepressant Effects of Nitrous Oxide

Lead Sponsor:

University of Chicago

Collaborating Sponsors:

The Alfred

Conditions:

Major Depressive Disorder

Treatment Resistant Depression

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to ...

Detailed Description

The investigators are conducting a randomized controlled trial to evaluate the antidepressant effects of nitrous oxide in people with Major Depressive Disorder (MDD). MDD is a global medical condition...

Eligibility Criteria

Inclusion

  • Adult (≥18 years, both sexes)
  • DSM-5 criteria for MDD without psychosis, as determined using a structured clinical interview \[Mini International Neuropsychiatric Interview\], MDD, defined by a pre-treatment score \>16 on the HDRS-21 scale and meeting DSM-5 for MDD

Exclusion

  • A current or past history of bipolar disorder, schizophrenia, or schizoaffective disorder.
  • Current obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses
  • Active suicidal intention, as determined by clinical interview assessment tool (Sheehan-STS) and clinical examination
  • Active or recent (\<12 months) substance use disorder; excluding nicotine
  • Administration of NMDA-antagonists (e.g., ketamine) in previous 3 months
  • Ongoing treatment with ECT
  • Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease
  • Pregnancy or breastfeeding
  • Any contraindications to the use of nitrous oxide (e.g., pneumothorax, middle ear occlusion, elevated intracranial pressure, chronic cobalamin or folate deficiency unless treated with folic acid or vitamin B12).

Key Trial Info

Start Date :

June 30 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

172 Patients enrolled

Trial Details

Trial ID

NCT05357040

Start Date

June 30 2021

End Date

December 1 2026

Last Update

October 7 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of Chicago Medicine

Chicago, Illinois, United States, 60637

2

The Alfred Hospital

Melbourne, Victoria, Australia, 3004